The Office of AIDS Research (OAR) of the National Institutes of Health. OAR sets scientific priorities, enhances collaboration, and ensures that research dollars are invested in the highest priority areas of scientific opportunity that will lead to new tools in the global fight against AIDS.
Trans-NIH describes the collaboration. The NIH collaborates with its institutes, centers, and offices, sharing financial resources, materials, or specimens. Often, it is sharing actual scientific expertise. By maximizing resources, these trans-NIH initiatives serve to advance medical research in all disease areas and across the basic, translational, and clinical research continuum. Trans-NIH initiatives serve to advance medical research in all disease areas and across the basic, translational, and clinical research continuum.
The OAR Budget for FY 2016 is $3.1 Billion
It is essential to point out that because AIDS affects virtually every organ system, with a myriad of HIV-associated infections, malignancies, co-morbidities and clinical complications, NIH AIDS research supports a vast portfolio that also includes research on these related illnesses and conditions, such as tuberculosis; Hepatitis; and AIDS-associated cancers, neurologic complications, and cardiovascular conditions. OAR coordinates the scientific, budgetary, and policy elements of this diverse trans-NIH research program. OAR has established comprehensive trans-NIH planning, budgeting, and portfolio analysis processes to identify the highest priority areas of scientific opportunity, enhance collaboration, minimize duplication, and ensure that precious research dollars are invested effectively.
NIH will train the next generation of AIDS researchers around the world to foster collaboration, innovation, and transformative research.
Research related to the potential for a cure or lifelong remission of HIV infection is a key NIH research priority, which involves research across a number of scientific areas. Although combination ARV therapy has changed the face of HIV infection by improving health, prolonging life, and substantially reducing the risk of HIV transmission, research toward a cure is a high priority for NIH because of the continued risks for HIV- associated clinical complications even with ARV use, the side effects of the drugs, and because the need for lifelong ARV therapy is in itself a heavy burden on HIV-infected persons.
The experience of Timothy Ray Brown, the so-called “Berlin Patient”* has demonstrated that a cure for HIV infection is possible. Subsequent research has shown that cure or lifelong HIV remission will be a difficult goal to achieve. Yet the same research has demonstrated that prolonged and sustained HIV remission with concomitant absence of chronic immune activation may be possible off ARV therapy, even if cure or lifelong remission has not yet been achieved apart from in the case of the Berlin Patient.
*[More information about the Berlin Patient on this Stealthcare page.]